Silver Book Fact

MRSA infections increase in older patients

In 2008, 75% of healthcare-associated invasive MRSA infections occurred in patients older than 50, with 46% in patients older than 65%.

Kallen, Alexander J., Yi Mu, Sandra Bulens, Arthur Reingold, Susan Petit, Ken Gershman, Susan M. Ray, Lee H. Harrison, Ruth Lynfield, Ghinwa Dumyati, John M. Townes, William Schaffner, Priti R. Patel, Scott K. Fridkin; for the Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. Healthcare-Associated Invasive MRSA Infections, 2005-2008. JAMA. 2010; 304(6): 641-7. http://jama.jamanetwork.com/article.aspx?articleid=186385

Reference

Title
Healthcare-Associated Invasive MRSA Infections, 2005-2008
Publication
JAMA
Publication Date
2010
Authors
Kallen, Alexander J., Yi Mu, Sandra Bulens, Arthur Reingold, Susan Petit, Ken Gershman, Susan M. Ray, Lee H. Harrison, Ruth Lynfield, Ghinwa Dumyati, John M. Townes, William Schaffner, Priti R. Patel, Scott K. Fridkin; for the Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program
Volume & Issue
Volume 304, Issue 6
Pages
641-7
URL
Read Full Resource

Categories

  • Cost of Disease
  • Age - A Major Risk Factor

Related Facts

  • >20% of drug-resistant pneumonia in nursing homes
    More than 20% of drug-resistant cases of pneumonia in 2010 occurred in nursing home residents.  
  • Primary sources of HAIs
    Around 2/3 of all HAIs are central-line associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia. Surgical site infections and Clostridium difficile (C. difficile) are also common HAIs.  
  • 1 in 10 HAI hospital stays from sepsis
    1 in 10 hospital stays with HAIs have a principal diagnosis of septicemia.  
  • Significant increase of penicillin-resistant Streptococcus penumoniae
    High-level penicillin-resistant Steptococcus pneumoniae increased 1,000-fold over 17 years.  
  • Drug resistant infections cost $16.6 – $26 billion to US healthcare system annually
    Drug-resistant infections cost the U.S. healthcare system between $16.6 and $26 billion in extra costs each year.